A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)

NCT02078960 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
10
Enrollment
INDUSTRY
Sponsor class

Stopped Inability to accrue additional sites and enroll an adequate number of subjects.

Conditions

Interventions

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.